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ABSTRACT
In this dissertation, DNA recombinase Flp modified variants were developed for
gene editing. The Flp recombinases can perform recombination reactions to modify the
DNA sequence on the Flp recombination target (FRT). The Flp can recognize the DNA
sequences，which resemble the wild-type FRT when modified. The Flp modified
variants show potential values for genomic engineering because such FRT-like sequences
as targets are widespread in the human genome. Our goal is to evolve the Flp variants on
FRT-like targets in the human genome for safety and efficiency, correcting the genome
mutations which cause the genetic disease.
Gene editing relies on site specificity nucleases such as transcription activator-like
effectors nuclease (TALEn), Zinc finger nuclease, or CRISPR/Cas9. Flp, as a site
specificity recombinase has different mechanisms on the DNA modification. The
recombinases do not cut the DNA by removing the fragment as nucleases and show better
safety in gene modification. That's the reason we chose site specific recombinases as our
research target.
We chose the FRT-like sequences in the human interleukin gene and beta
hemoglobin gene as our target for Flp evolving. To improve the specific activity of these
Flp variants on targeted FRT-like sequences in human cells, DNA-binding domain from
transcription activator-like effectors (TALE) which are found in the plant pathogen
Xanthomonas were fused to the Flp variants, to form Flp-TAL variants. The DNAiii
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binding domain from TALE can be programmed to recognize the designated DNA
sequence and improve the specificity binding of the nearby working domain.
The Flp-TAL variants have been proven able to perform DNA recombination in
human cells. My work concerns evolving Flp-TAL variants to recombine the FRT like
sequences that are located in the human gene, and testing them under model conditions in
human cells.
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CHAPTER 1
INTRODUCTION
Genome manipulation at desired locations opens an opportunity to develop model
cells, model organisms, and to correct genetic disorders. Recent advances in the
developing field of genome engineering are primarily attributed to site-specific DNA
nucleases: mainly zinc finger nucleases (ZFNs), transcription activator-like effector
nucleases (TALENs), and nucleases that are based on the clustered regularly interspaced
short palindromic repeats/Cas9 systems (CRISPR/Cas9) (e. a. Cong L 2013, e. a. Miller
JC 2011). However, several inherent properties of site-specific nucleases, which include
the very necessary to introduce double strand breaks and the reliance on the cell’s DNA
repair machinery to process these breaks, prompted the researchers to look for other
genome engineering systems that utilize different DNA manipulation mechanisms. Apart
from converting CRISPR/Cas9 into site-specific deaminases (Komor AC 2016, Kim YB
2017), site-specific tyrosine and serine DNA recombinases are attractive alternatives
(Grindley, Whiteson and Rice 2006).
The burst of the nuclease-based genome engineering applications is triggered by
two main factors: the efficiency of cleavage of genomic targets by these composite
nucleases and the relative ease with which their target recognition units can be
assembled, especially for the CRISPR/Cas9-based systems. Although site-specific
nucleases can locate and cleave their targets, these enzymes are not able to complete the
1
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genome modification task: the host DNA repair machinery is required to seal the
introduced DNA breaks either by the non-homologous end joining (NHEJ) or by the
homologous DNA repair mechanisms.
Compared to site-specific nucleases, other genome manipulation tools, the sitespecific DNA recombinases do not generate double strand breaks in DNA and can
accomplish the genome modification task without any assistance from the host DNA
repair machineries. Popular site-specific recombination systems employed for genome
engineering applications include Cre/lox from coliphage P1, Flp/FRT from 2 micron
plasmid of S. cerevisiae, and φC31/att from Streptomyces phage φC31.
Tyrosine recombinases, such as popular genome engineering tools Flp and Cre, are
highly specific for their targets, versatile in performing DNA manipulation reactions and
can be easily regulated. However, the native recombinase can only be useful for genome
engineering if the native targets for tyrosine recombinases are pre-introduced into a
genome locale of interest. This makes it impossible to utilize the original tyrosine
recombinases in the applications that are aimed to manipulate the genome in unmodified
cells.
Fortunately, the recombinase variants which utilize genomic sequences resembling
native recombination targets can be evolved (Buchholz F 2001, Sarkar I 2007, e. a.
Bolusani S 2006, Shultz JL 2011). The total number of target-like sequences in a genome
can be quite substantial: the human genome, for example, has about 600,000 of the FRTlike sequences that have different levels of homology to FRT, the native recombination
target for Flp recombinase. This number corresponds to one FRT-like sequence per 5 kb –
such density allows DNA manipulations essentially in all genomic locations provided the
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variants that are evolved to recombine with these sequences can bind them in their native
chromosomal environment, outcompeting other DNA binding proteins, primarily histones.
It appears that tyrosine recombinases lack the well-defined DNA binding motifs with
clear rules that specify which residues need to be mutated to achieve the target specificity
switch (Guo, Gopaul and van Duyne 1997, Chen, et al 2000). Moreover, the entire structure
of tyrosine recombinases seems to take part in the functional target recognition (Buchholz
F 2001, e. a. Bolusani S 2006). Such a mode of protein-DNA binding restricts the evolution
process of the target-specific tyrosine recombinase variants to mainly random target-linked
mutagenesis although the modification of the residues that participate in the protein-DNA
recognition can speed up the evolution process (Buchholz F 2001, Sarkar I 2007, e. a.
Bolusani S 2006, Shultz JL 2011, Karpinski J 2016, L. F. Shah R 2015).
Instead of applying protein evolution, a different approach was used to engineer targetspecific variants of tyrosine recombinases that have two domains with distinct functions:
target binding and catalyzing (Grindley, Whiteson and Rice 2006). In this approach, a
modified catalytic domain with relaxed target specificity is fused with the DNA binding
domain, target specificity which can be easily programmed. This approach was
successfully applied to create different hybrid tyrosine recombinases, such as zinc-finger
recombinases (ZFRs), TALE recombinases,(TALERs), and Cas9 recombinases(recCas9).
Each of these was created by fusing the activated catalytic domains of the invertase Gin or
the resolvase Tn3 with the DNA binding domains of either zinc fingers, TAL effectors, or
the catalytically inactive Cas9 protein, respectively (Akopian A 2003, Gordley RM 2007,
Mercer AC 2012, Chaikind B 2016).
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This modular design concept when proteins with different functional properties are
fused together was also successfully applied to develop hybrid site-specific nucleases: zinc
finger nucleases, or ZFNs, and transcription activator-like effector nucleases, or TALENs,
that are composed of a nonspecific DNA nuclease FokI and the respective DNA binding
domains with programmable target specificity (Kim YG 1996, Christian M 2010). Target
affinity and specificity in these modular systems can be modified by changing the number
of the target recognizing units in their DNA binding domains to achieve the optimal
balance between target specificity and non-specific DNA binding (e. a. Miller JC 2011,
Carroll and Porteus 2005, Urnov FD 2005, e. a. Miller JC 2007, Cermak T 2011, Gaj T
2013).
The modular design can be applied to develop hybrid tyrosine recombinases that would
benefit from additional target-specific DNA binding domains which can stabilize the
recombinase variants on their targets, thus increasing their activity. In principle, two classes
of the hybrid tyrosine recombinases can be developed that will differ at the level of target
specificity of their recombinase modules. In the first class, both modules of the hybrid
enzyme – the tyrosine recombinase variant and the extra DNA binding domain – can be
evolved or engineered to be specific for a particular genomic target sequence of interest.
As such, this class of the hybrid tyrosine recombinases can be the most target specific
genome engineering tool available, but the modification of the target specificity of their
recombinase module can require an effort.
In the second class of the hybrid tyrosine recombinases, the two modules differ at the
level of their target specificity: the recombinase module can be evolved to have broad
specificity toward genomic target sequences while the extra DNA module can be
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engineered to deliver this recombinase module to a particular target-like sequence where
the recombination reaction will take place. The recombinase module in these hybrid
recombinases should be relatively weak to reduce the probability of recombination of the
genomic target sequences on its own, thus preventing abnormal recombination events.
However, the recombination activity of this weak module should be stimulated upon
binding to the desired target sequence due to the target binding stabilization by the extra
DNA binding domain. Since the target specificity of the recombinase module can be made
broad, this module can be used to generate hybrid recombinases of different target
specificity simply by changing the target specificity of the extra DNA binding module. As
such, in contrast to the hybrid tyrosine of the first class, the effort to modify the target
specificity of the hybrid tyrosine recombinases of the second class will be relatively low.
In this work we analyzed the suitability of both classes of the hybrid tyrosine
recombinases for genome engineering. For this, we developed Flp-TAL recombinases,
which are composed of a variant of Flp recombinase with either narrow or broad target
specificity that are fused with the DNA binding domain of the TAL effectors (TAL DBD).
Using a simplified protein evolution approach, the Flp variants for Flp-TAL were evolved
to recognize FRT-like sequences in the human β-globin gene. We examined the integration
and deletion activity of the Flp-TAL recombinases in intact human HEK293 cells and
found that only the hybrid Flp-TAL variants but not the respective target-specific Flp
variants were able to efficiently perform these reactions. We also demonstrated that the Flp
variant with broad specificity toward FRT-like sequences can be indeed fused to TAL
DBDs of different target specificity to direct the variant to new genomic target sequences.
We estimated that the efficiency of the integration and deletion reactions mediated by the
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Flp-TAL variants is about 0.1% and 10% respectively, which is comparable to that of wildtype Flp. Our results suggest that hybrid tyrosine recombinases can be developed into an
attractive genome engineering platform.

CHAPTER 2
BACKGROUND
Gene editing can be used to correct genetic mutations in the human genome
which can cause genetic disease. The genetic diseases like common sickle cell disease
(SCD) and neurofibromatosis (NF) are caused by a single gene mutation that may in
future be cured by gene therapy. Since 1989, the first gene therapy was used in clinical
experiments (Rosenberg SA 1990). Currently, the safety and efficiency of gene therapy
has developed significantly, but it still has not met the expectations of clinical
applications. Early on, gene therapies were more focused on delivering the exogenous
genes to restore the proper biological function (Hanna, et al. 2017). The viral vectors,
which were used as gene delivery vehicles in gene therapies, have a high probability of
inserting vectors randomly in the genome. That situation does not just miss the target of
gene therapy but also activates the tumor-promoting pathways in the cell. The research of
gene therapy on severe combined immunodeficiency (SCID) had shown such a risk
(Boudes 2014).
An alternative treatment option for inherited monogenic diseases is correcting the
gene mutation by gene editing on the cellular level, which may restore partial cellular
function. When the cells restore the function, the functional cells are transferred to
replace the malfunctioning ones to regain function.
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My research aims to use site-specific Flp/FRT recombinase to correct the
pathogenic mutation in mammalian cells.

2.1

Site-specific recombinases

Site-specific DNA recombinases can bind to specific DNA sequences called
recombination targets and catalyze DNA rearrangement. With high-specificity and
efficiency, site-specific DNA recombination has become an essential genomic
engineering tool (Kilby, Snaith and Murray 1993). Site-specific recombinases can
rearrange DNA sequences in several ways: integration/deletion, inversion, and
replacement (Gibb B 2010) in bacteria, plant and human cells (Figure 2-1). By deletion, a
small circular DNA fragment excised from the genome, or a circular DNA plasmid is
severed into two small circular plasmids. The integration and excision are reversible
processes while the recombination targets are still in the genome. In replacement, the
gene cassette is exchanged between two different genomes.
There are variants of site-specific recombinase working on identical DNA
sequences from different origins that can be used as tools for gene editing (Stark 2014,
Brown W R 2011, Altschul, et al 1997, W. K. Grindley ND 2006) (Table 1).
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Figure 2-1 Three main types of DNA rearrangements catalyzed by site-specific
recombinase: (A) deletion/integration, (B) inversion, (C) The gene/cassette replacement,
or recombinase-mediated cassette exchange.

2.2

Flp recombinase

Flp, as a site-specific recombinase, was derived from the 2-micron plasmid of the
baker's yeast Saccharomyces cerevisiae, and is part of a dual strategy system that
maintains the plasmid's high copy number (Utatsu, et al 1987)(Figure 2-2). Flp
recombinases can perform recombination without any accessory proteins in mammalian
cells. For Flp, the efficiency of the integration and deletion reactions was about 0.1% and
10%, respectively.
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Table 1 Examples of recombinases and their biological functions (6-9)

integrase

Target

Origin

Biological Function

attP

bacteriophage

Integration of the viral

attB

lambda

genome into the
bacterial chromosome

XerCD

cer (plasmid

Escherichi coli

ColE1)

Resolving chromosome
and plasmid dimers

psi (plasmid
SC101)
Cre

loxP

bacteriophage P1

Circularization of linear
phage genomes.

Flp

FRT

2 micron plasmid

Maintaining the

from Saccharomyces

plasmid copy number

cerevisiae
φC31

attP/attB

Streptomyces phage

Integration of the viral

φC31

genome into the
bacterial chromosome
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Figure 2-2: The 2-micron plasmid of the yeast Saccharomyces cerevisiae and the Flp
Recombination Target (FRT) sequence. (A) The 2-micron plasmid from which Flp is
encoded also contains three genes (REP1, REP2, and D, which are not shown on the
figure) that regulate the expression of Flp. When recombination occurs, two FRT
sequences approach each other to make the plasmid dumbbell-shaped. The recombination
relocates the genes on the plasmid and controls the expression of the REP1 gene, which
controls the replication of the 2-micron plasmid. The 2-micron plasmid's copy number is
controlled by such a Flp-FRT recombination system. (B) FRT is composed of two 13based pair-inverted repeats, which bind to the recombinase, and an 8 base pair spacer.
2.2.1

The mechanism of Flp recombination
Flp is a member of the tyrosine family site-specific recombinases, which also

include Cre, XerC/D, and λ-Integrases. This family name comes from the highly
conserved tyrosine residue, which plays a key role in the recombination reaction. The 343
tyrosine residue in the Flp is essential for the catalytic function, but does not contribute to
substrate recognition (11).
The tyrosine residue at position 343 in Flp attacks the DNA and links to it
covalently during the strand exchanging stage in the recombination reactions. Flpmediated recombination begins with tetramerization of four Flp monomers to two FRT
molecules; then a Holliday-junction intermediate is formed (Figure 2-3, Figure 2-4).
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After two strand cleavages occur, the Holliday intermediate is resolved. Later, the
recombination products are released.

Figure 2-3: Site-specific recombinase Holliday intermediate formation and resolution.
DNA rearranges by building and resolving the Holliday construction in recombination.
(A) The Flp and DNA form a tetramer and activate the recombination reaction. (B) DNA
cleavage occurs in single-stranded DNA and forms a nick. (C) The first DNA exchange
produces a Holliday intermediate. (D)The second DNA cleavage and exchange in
Holliday intermediate. The purple arrows show where the DNA cleavage occurs.
(E)Holliday intermediate resolves. (F)The recombination products release.
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Figure 2-4: The 3D Holliday construction of the Flp and DNA (purple) tetramer.

2.2.2

Recombinases can be used as tools for genome manipulation
Recombinases can be used as tools for genome manipulation. However, the use of

the Flp recombination system in genome engineering is limited because the native Flp
can only recognize the wild-type FRT sequence. Thus, the wild-type FRT site has to be
introduced into the genome before genomic manipulation is performed.
As a tyrosine recombinase, Flp lacks a distinct DNA binding motif with clear
rules that dictate which residues require mutations to achieve target-specific
transformation (Guo F 1997, Chen Y 2000). Furthermore, the entire structure of tyrosine
recombinase appears to be involved in functional target recognition (Buchholz F 2001) .
This protein-DNA binding pattern limits the evolution of target-specific tyrosine
recombinase variants primarily by random target linked mutagenesis, although
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modification of residues involved in protein-DNA recognition accelerates evolutionary
processes (Shultz JL 2011, Karpinski J 2016, L. F. Shah R 2015, Ingram 1957).
However, the mutated, or evolved Flp variants can bind to an FRT-like sequence
in the human genome. Modifying the different types of amino acid residues in Flp can
alter or relax the target specificity of Flp, thus enabling the modified Flp variants to
combine with the sequence, which can be called FRT-like sites (e. a. Bolusani S 2006,
Voziyanov Y 2003).
It has been proven that evolved Flp variants can be used as an efficient method of
site-specific recombination in mammalian cells. In mammals, there are a large number of
DNA sequences in the genome that are similar to the FRT-like sites.
2.3

The selection of the target in human genome

Several FRT-like sites in the human genome are identified through sequencing
analysis by software. Some of the sites are selected as the targets of the research because
of their location in the genome. The modified Flp variants, which can perform
recombination reaction at these sites, can be used as genomic engineering tools with
potential clinical value.
2.3.1

The FRT-like sequence in the human interluekin gene
We chose a FRT-like sequence in the human interleukin gene as one of our

targets, and name it IL10A(Figure 2-5 B).
2.3.2

The FRT-like sequence in the human δ-globin gene
For our experiments, we chose three FRT-like sequences that are located upstream

of the human δ-globin gene and within the δ-globin and β-globin genes: FL-61, FL-63, and
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FL-71, respectively, which are separated from each other by 2.7 kb and ~7.5 kb,
respectively (Figure 2-5 A and B).
These FRT-like sequences, as well as other genomic FRT-like sequences, can have
several potential upstream and downstream TAL recognition sequences since the
requirements for the TAL recognition sequences are quite relaxed – the only major
prerequisite is a thymine at the position N-1 of the sequence: 5’T (Lamb BM 2013). We
reasoned that to be useful in targeting Flp-TAL recombinases to the desired FRT-like
sequences and to be easily manageable from the technical point of view, the TAL module
has to recognize the DNA sequence of 15-24 bp in length. We also reasoned that the TAL
binding sequence should be separated from the recombinase binding element of the FRTlike sequence by 3 to 12 base pairs to avoid steric clashes between the hybrid recombinase
modules or their significant spatial separation.
Additionally, we reasoned that the length of the TAL binding sequences should
correlate with the degree of similarity between the Flp binding elements of the FRT-like
sequence and that of FRT: the weaker the similarity, the longer the TAL recognition
sequence. Based on the above considerations, we decided to test the TAL biding sequences
of 15 bp in length (except for the upstream 24-bp TAL binding site for FL-71) that are
separated from FL-61, FL-63, FL-71 by 4-5 bp (Figure 4- 2C).
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Figure 2-5: FRT-like sequences FL-61, FL-63, FL-71 and FL-L10A. (A) Relative location
of FL-61, FL-63, and FL-71 in the human beta globin genome. (B) Alignment of FRT,
FL-61, FL-63, FL-71and FL-IL10A. The base pairs in FL-61, FL-63, FL-71and FLIL10A that differ from the corresponding base pairs in FRT are shown as lower case bold
black letters. (C) FL-61_TAL, FL-63_TAL, and FL-71_TAL sequences. 5’T bases for
the TAL recognition sequences (marked by blue arrows) are shown in red.
2.4
2.4.1

Evolution of target-specific Flp variants

Generation of Flp variant libraries
We need a gene library that contains large mutations of Flp variants. However, in

a laboratory environment, for a single functional protein, a large number of mutations can
be accumulated in a short time by biochemical means, and screened to a specific target,
so that the protein enhances a particular function and characteristics. In the past, artificial
mutagens have been used extensively to achieve such a purpose. But now, with PCR
methods, higher mutation efficiencies can be obtained to accumulate the gene library.
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The techniques for the directed evolution techniques include error prone PCR and DNA
shuffling.
2.4.1.1

Variants’ gene pools
The Flp variants’ gene pools have been created by a method error-prone PCR.

The error-prone PCR can introduce random mutations into the DNA sequence when
amplifying DNA. The error-prone PCR can generate mutated gene libraries by controlled
condition PCR. Leung first discovered the error-prone PCR in 1989 (Leung, Chen and
Goeddel 1989). Cadwell and Joyce (Cadwell RC 1992) amended the protocol in 1992.
The parameters altered in the PCR reaction can introduce random mutations in the gene
fragment.
In my experiments, the Flp mutant library was obtained via error-prone PCR
performed by my laboratory colleagues and added to the FLP mutant variant FL4.
2.4.1.2

DNA shuffling
DNA shuffling as a method can be used to generate a library of target genes with

varying mutations for Flp variants (Shultz JL 2011). The mutated Flp DNA mixture will
be treated with DNaseI. DNaseI can digest DNA into small fragments, and then
reconstruct the DNA via PCR without additional primers (Figure 2-1). The enriched
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mutated Flp variants library will be obtained.

Figure 2-6: The shuffling of the Flp variants’ library. When digested by different
concentrations of DNase I, the DNA sheared into small fragments (B, D). Different
concentrations of DNase I will produce different sizes of DNA fragments. The DNA
fragments of around 500 bps will be taken to run the assembling PCR. The DNA
fragments will be assembled to their original size, which are about 1.5kb, the size of Flp
variants’ sequences (C, E). Using primers for Flp variant sequences, the PCR can amplify
the original size of Flp variants’ sequences with enriched mutations (C, F). M: 2-log
ladder marker.
2.4.1.3

Functional screening of Flp libraries in E.coli
To pick up functional Flp variants, Flp variant libraries will be cloned into a

selection plasmid, transformed into E.coli, and screened for variants with high activity
and site-specificity for target sequences. The plasmid is based on a pBAD expression
vector, which can control the expression level of Flp variants by adjusting the
concentration of arabinose. The Flp variant libraries which can activate the recombination
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on the target sequences will change the construction of the plasmid. Both positive and
negative selection can be used to select Flp variants (Figure 2-7).

Figure 2-7: The positive selection system (A) and the negative selection system (B).Flp
variant libraries cloned into the positive selection system (A). Before the recombination,
the primers (the red arrows in the picture) which combine on the lacZ gene are unable to
amplify the DNA fragment by PCR. After expression, when the Flp variants expressed
from the plasmid activate the recombination on the right target (FL-71), the LacZ part in
the plasmid will be inverted. Using the primers that combine the LacZ part, the sequence
that contains proper Flp variants’ sequence will be PCR amplified. In the negative
selection system (B), when Flp variants activate the recombination on the wrong target
(between FL-71 and other FRT-like sequence FRT-sp71, which has the spacer from FL71 and the recombinase binding sequences of FRT), the LacZ part in the plasmid will be
deleted, and the primers that combine the LacZ part cannot amplify the over-active Flp
variants. If the Flp variants are unable to activate the recombination on the FRT-sp71, the
DNA fragment that contains the Flp variant sequence can be PCR amplified by the
respective primers.
In positive selection, the Flp variants’ libraries that have recombination activity
can be selected. In negative selection, the Flp variants’ libraries that have over activity on
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other FRT-like sequences will be screened out. In such a system, the Flp variants with
both high recombination activity and site-specificity can be screened out.
A color screening of the E.coli system will be used to identify Flp variants from
the Flp variants’ libraries. This color screening system is also a negative selection system
on solid bacterial culture. The Flp variants’ expression plasmid will be transformed into
E.coli with a reporter plasmid, which contains the lacZ gene flanked by FRT-like sites.
After correct recombination occurs, the lacZ gene will be deleted from the reporter
plasmid. The deletion of lacZ can be observed by the color of colonies (Figure 2-8). Flp
variants which perform correct recombination will be expressed in the white E. coli
colonies. The white colonies can be picked, and the Flp variants can be obtained from
those colonies. Flp variants obtained from the screening will re-pass the pathway of
directed mutation and selection to achieve higher efficiency.
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Figure 2-8: The Color selection system. The reporter plasmid (A), which contains
the lacZ gene, can turn E.coli colonies blue color on the X-gal plate (B). When the
Flp variant expression plasmid, which has been co-transformed with the reporter,
performs a deletion recombination, the lacZ gene from the reporter plasmid will be
deleted (lacZΔ), causing the colonies to turn white. When the plasmids are collected
from the E.coli colonies, the size of the reporter plasmid can also show a difference
from the deletion of the LacZ gene (D).
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2.5

Testing of the target-specific Flp variants’ activity in eukaryotic cells

We designed the following system to detect the activity of Flp variants in
eukaryotic cell culture.
2.5.1

Deletion assay in eukaryotic cells
The deletion activity of Flp variants is significantly higher than integration

activity. We test the deletion activity of the variants on episomal plasmid in eukaryotic
cells. The variants will be cloned into a eukaryotic expression plasmid. The designed
reporters can be used to check the recombination activity by the fluorescent color of the
cells (Figure 2-9). Chinese hamster ovary (CHO) cells and human embryonic kidney 293
cells will be used for the testing.

Figure 2-9：The deletion reporter in the eukaryotic model cell. The reporter
contains the EGFP gene, which is flanked by two FL-71 sequences that
enable the cells to show green fluorescent color. When proper
recombination occurs, the EGFP gene will be deleted by Flp variants. The
CMV promoter will directly activate the DsRed gene, which causes the cells
to show red fluorescent and to lose its green color.
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2.5.2

Integration assay in eukaryotic cells
In order to test the integration activity of the Flp variants in mammalian cells, the

Flp variants will also be tested using the integration assay in eukaryotic model cell CHO
(Chinese hamster ovary) or HEK 293 (Human Embryonic Kidney 293) cells. In
integration assays, a designed color display reporter and a pre-modified model cell line
will be used (Figure 2-10). In 48 hours, the color change will display whether correct
recombination has happened. The cells will be collected for PCR analysis to verify the
integration.

Figure 2-10 The integration reporter in eukaryotic model cell.
(A) A CMV promoter is located upstream of the FL-71 site in
the coming reporter. In the mode cell genome, the platform
reporter with FL-71 site and DsRed gene cannot express red
color because of the lack of promoter. (B) When correct
recombination occurs, the reporter will integrate into the cell
genome, and the CMV promoter will activate the DsRed
gene, causing the cells to turn red.

2.6
2.6.1

The development of Flp-TAL variants

TALE construction
By fusing the target recognition units in the DNA binding domain from zinc

finger nucleases, or ZFNs, and transcription activator-like effector nucleases, or
TALENs, the target affinity and specificity of Flp variants can be modified to achieve an
optimal balance between target-specific and non-specific DNA binding (Porteus MH
2005, Urnov, et al 2005).
To improve the specificity of Flp variants on target FRT-like sites, the Flp
variants were fused to the designed domains. Transcription activator-like effectors
(TALE) that are found in the plant pathogen Xanthomonas have a DNA-binding domain
(DBD). A series of repeat 33-35 amino acid modules constructed these DBDs, which we
called "TAL" domains. In each module, two adjacent repeat variable di-residues (RVDs)
mediated the binding of a single nucleotide (Figure2- 11), There are 'NI' RVD codes for
'A' DNA base, 'HD' for 'C', 'NG' for 'T' and 'NN' for 'G' DNA base. Changing the RVDs,
TAL can be modified to bind the designed DNA sequence (Scholze H 2011, Mussolino C
2012). Fusing the TAL to FokI nuclease has recently been achieved (Mussolino C 2012,
Bedell, et al 2012), which gives the protein binding specificity for the designed DNA
sequence. Thus, evolved Flp variants will be fused with TAL domains; they will have
obtained more specific recombination activation at target sites.
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Figure 2-11： The 3D model of TAL. The RVDs are specific to their targets， and the
code of how they bind to a base pair has been solved. The RVDs can be easily engineered
to bind specific DNA targets. (The figure is downloaded from (Osgood 2013)
http://parts.igem.org/Part:BBa_K1189000 and modified).
2.6.2

Flp-TAL variants
In my experiments, the TAL RVD domain will be fused with selected Flp variants

in the vector plasmid. TAL domains will be assembled using the Golden Gate TALEN
Kit from Voytas Lab Golden described in Cermak et al. 2011 (Cermak T 2011). This Kit
was designed for constructing TAL-linked nuclease FokI. The vectors from Golden Gate
TALEN Kit were modified to link the TAL domain with Flp variants (Figure 2-12). The
fused protein can be expressed and selected for recombination activity. For Flp variants
which bind on their own targets, two different TAL domains will be designed for
different binding regions. The Flp part will act as the catalytic domain, and the TAL
module will serve as a DNA binding domain.
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Gene sequences with TAL targets can be added to the selection vector for e.coli
or eukaryotic cells. In this way, the selection of FL variants can be made with the TAL
domain or without it. We will compare the two methods in the experiment, which can
produce variants that are more active. The activity of Flp-TAL variants will be tested in
the same ways as Flp variants.

Figure 2-12： Flp-TAL recombinases. (A) General mode of target binding by Flp-TAL
recombinases. (B) Relative arrangements of the Flp and TAL recognition sequences
depending on the connection between the Flp and TAL modules. (C) Schematic of the
Flp-TAL variants.
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CHAPTER 3
METHODS
3.1
3.1.1

The construction of the Flp variants’ libraries

DNA shuffling
The DNA shuffling method originated from Cadwell and Joyce (Cadwell RC

1992). We researched this method and made extensive modifications for expanding the
Flp variants’ library, ultimately creating our own protocol:
1. The DNA fragment was treated with DNase I (Roche®) for analytical
digestion:
The activity of the enzyme DNase I (Roche®) varies with storage time. To obtain
300-400 bp DNA fragments for shuffling, analytical digestion is required to determine
the optimal conditions before digesting the DNA each time.
The DNA fragment was digested with different concentrations of the DNase.
DNA

Tris

MgCl2

DNase I

1.5 µg

50 mM

10 nM

0.5 U

1.5 µg

50 mM

10 nM

1U

1.5 µg

50 mM

10 nM

2U

1.5 µg

50 mM

10 nM

5U

1.5 µg

50 mM

10 nM

10 U

1.5 µg

50 mM

10 nM

20 U

The final volume of each reaction is 10µl. The reaction was placed on ice for 5
minutes. Then it was heated to 80 degrees for ten minutes to stop the reaction.
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The reaction productions were loaded on agar gel, and the electrophoresis was run
to test the best conditions.
2. DNase I digestion for shuffling
The digestion was repeated under the best conditions, which made the DNA
fragments most closed to 300-400 bp. The volume of each reaction was 50 µl. The
reaction was placed on ice for 5 minutes. Then the reaction was stopped by adding the
binding buffer from GeneJET Genomic DNA Purification Kit (Thermo Scientific™®
K0721).
The DNA reaction mixture was purified by GeneJET Genomic DNA Purification
Kit (Thermo Scientific™® K0721). The results were checked by agarose gel
electrophoresis.
3. The first round of PCR
Reaction setup:
DNA fragment

10X Standard

mixture

Taq Reaction

dNTPs

Taq

Total volume

Buffer
20µl

10µl

200 µM

2.5 Unit

100µl

40µl

10µl

200 µM

2.5 Unit

100µl
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Thermocycling conditions for the PCR:
Step

Temp

Time

Initial Denaturation

94℃

30''

40 Cycles

94℃

30''

45℃

1'

72℃

2'

Final Extension

72℃

10'

Hold

4℃

Check the PCR production with agar gel electrophoreses.
4. The second round of PCR
Reaction setup:
1st Round

10X Standard

PCR

Taq Reaction

produce

Buffer

1µl

5µl

Primer pair

dNTPs

Taq

1µM each

200 µM

1 Unit

Total volume

50µl
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Thermocycling conditions for the PCR:
Step

Temp

Time

Initial Denaturation

94℃

30''

23 Cycles

94℃

30''

45℃

1'

72℃

2'

Final Extension

72℃

10'

Hold

4℃

The PCR product was checked with agar gel electrophoresis. The product from
the second round of PCR is in the Flp variants’ library.

3.2

Bacterial Experiments

All the bacterial experiments used the E.coli strain NEB 10-beta [araD139Δ(araleu)7697 fhuA lacX74 galK (ϕ80Δ(lacZ)M15) mcrA galU recA1 endA1 nupG rpsL
(StrR) Δ(mrr-hsdRMS-mcrBC)] from New England Biolabs ®
3.2.1

The construction of Flp expression vector and reporter vector
The plasmid used in this experiment was based on commercial plasmids. These

commercial plasmids were purchased from the website Addgene (www.addgene.org). It
was modified by PCR with specific primers and spliced by the restriction endonuclease.
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PCR is a routine method. The restriction endonuclease was purchased from NEB(New
England Biolabs®) and used its protocol.
We subcloned the Flp variants into pBAD33 expression system from Thermo
Fisher Scientific® as a Flp variant expression system. The expression of the Flp variants
can be controlled by the concentration of the X-gal. The +/- liquid selection systems are
also based on the pBAD33 plasmid. [Figure 2-2, Figure 2-3]
Plasmids based on pBAD24 contain a lacZ gene flanked by two FRT-like
sequences that will be used as reporter plasmids to detect the activity of Flp variants in
solid bacterial culture screening.
3.2.2

Preparation of the competent cell
Both the expression and reporter vectors were transformed in E. coli bacterial

strains. These strains were initially made competent using the p24 reporter plasmid and
then used to transform expression plasmids to monitor activity and screening.
3.2.3

The bacterial screening in liquid culture
The ligation product of the inversion reporter and a Flp variant library were

transformed into bacterial cells and incubated with the inducer L-arabinose at the final
concentration 0.1% for 2.5 hours. Then, the transformed cells (0.3 ml) were transferred
into 20 ml of LB supplemented with chloramphenicol (35 µg/ml) and incubated
overnight. The reporter plasmids were then isolated and subjected to the PCR analysis to
identify those Flp variants that were able to invert the reporter.
3.2.4

The colony screening of FLP variants in bacterial culture
The deletion assays in E. coli were performed by the protocol form Voziyanov et

al (Voziyanov, Stewart and Jayaram 2002). the Flp variant library expression vector
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(pBAD33) was transformed into bacterial cells that harbored the deletion reporter
(pBAD24 (27)). After incubating the transformed cells with the inducer L-arabinose at
the final concentration 0.1% for 2.5 hours, the cells were plated onto LB/agar plates
containing X-gal to visualize the colonies in which the deletion of the lacZα cassette
occurred.
Viable Flp variants screened from bacterial experiments will further eukaryotic
cell experiments.
3.3

Fusion with TAL Domain

In the Flp-TAL design we utilized the TAL DNA-binding domain and the intermodular linker that were proven in other hybrid enzymes (Figure 1C). The full-size Flp
recombinase variant was fused to the TAL core DNA-binding domain that starts at the
position +152 (Δ152 truncation of the N-terminal segment of the TAL effector) and ends
at the position +95 of the C-terminal segment of the TAL effector (1). The Flp and TAL
modules were connected via linker L6 that was shown to support the highest level of
activity of the zinc-finger recombinases (Gaj T 2013). (Figure 2-12)
The protocol is followed by Golden Gate TALEN and TAL Effector Kit 1.0
(Addgene) (Z. R. Cong L 2012, Streubel J 2012).
A system developed by my colleagues in the laboratory allows us to easily
convert the FL and TAL fusion genes from a prokaryotic expression vector (P33) to a
eukaryotic expression vector (pog) by a simple cleavage, linkage, and transformation.
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3.4

Experiments in mammalian cells

Human embryonic kidney cell 293 [HEK-293](ATCC ® CRL-1573™) were used
to analysis the activity of the Flp variants. Cells were cultured in regular DMEM medium
(Corning®).
Polyfect(Qiagen®) or DNA-In (Molecular Transfer®)was used for cell
transfection.
3.4.1

The construction of reporter vector and expression vector

Flp and Flp-TAL variants were expressed from the pOG100 vector, which is a
derivative of pOG44 (Anderson, Voziyanova and Voziyanov 2012). The pTarget reporter
vector is a derivative of the pDNA3 vector (Invitrogen).
The reporter vectors for the integration experiments were based on the pcTD
vector that is described in Anderson et al (Anderson, Voziyanova and Voziyanov 2012).
The platform reporter pCMV-FL-DsRed-neo and the incoming reporter pFL-puro-2AEGFP, which were used in the integration experiments in HEK 293 cells, were generated
as follows. The DsRed-neoR cassette from pIRES2-DsRed-Express (Clontech) was PCR
amplified and subcloned into pcTD downstream from the CMV promoter to obtain
pCMV-FL-DsRed-neo. FL sequence upstream of the DsRed-neoR cassette was
introduced during the amplification of the cassette. The puro R gene from pCAGGS-Flpepuro (Addgene plasmid 20733) and the EGFP gene from pIRES2-EGFP (Clontech) were
PCR-assembled into one gene through the connecting 2A peptide and cloned into pcTD
downstream from the CMV promoter to obtain pCMV-FL-puro-2A-EGFP. FL sequence
upstream of the puro-2A-EGFP gene was introduced during its amplification. The CMV
promoter in this plasmid was then deleted to obtain pFL-puro-2A-EGFP.
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For the experiments with the intact HEK 293 cells, the pCMV-FRT-puro-2AEGFP reporter was modified by cloning the PGK promoter from pDIRE 25 (Addgene
plasmid 26745) upstream of the promoterless hygro R gene.
3.4.2

Construction of Platform Reporter Cell Lines
HEK 293-FRT-DsRed-neo cell line was constructed by transfecting HEK 293

cells with pCMV-FRT-DsRed-neo, propagating them in medium supplemented with
neomycin (800 mg/l) and selecting for the red colonies. Several such colonies were
expanded and tested for single integrated platform reporter vector by Southern blotting;
the positive colonies were used in the integration experiments.
3.4.3

Integration assays in human cells
We first used the free reporter plasmid and expression plasmid to co-transfect the

cells to determine the Flp variants’ basic activity in human cells. After initially
confirming the activity of Flp variants, we used the model cells, which had integrated the
test genes into the cells of the genome, to detect Flp variant’s activity. 0.5 ug DNA was
transfected into a 70% confluence cell according to the protocol of the polyfect product .
After 48 hours, the discolored cells were searched by fluorescence microscopy and
recalled, placed in a 96-well plate, and the flora expanded until a sufficient amount (sixwell plate or 100 mm plate) was collected of the cells and further analysis of DNA was
performed.
The experiments to integrate pTarget into FL-61 and FL-71 were performed as
follows. HEK-293 cells were co-transfected, in 24-well plates, with pTarget (0.4 µg) and
the respective pOG100-Flp-TAL vector (1 µg). 48 hours post-transfection, 1/4 of the
cells were transferred into 6-well plates containing EMEM medium supplemented with
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hygromycin (550 mg/l). About 7 days later, individual red (FL-61 experiments) or green
(FL-71 experiments) hygromycin resistant colonies were transferred into 48-well plates,
expanded and analyzed by PCR and then sequenced.
3.4.4

Deletion assays in human cells

The experiments to delete the fragment of genome next to integrated pTarget were
performed by transfecting the respective cells in 24-well plates with pOG100-FlpTAL/71 (2 µg). 48 hours post transfection, all cells were transferred into 6-well plates,
allowed to become confluent, collected, and analyzed by PCR and sequencing.
3.5

Other Methods

Plasmid DNA was isolated using GeneJET Plasmid Miniprep Kit (Thermo).
Amplification of the DNA fragments used for cloning was performed using Pfu-Ultra
polymerase (Agilent Technologies). PCR analysis of the mammalian genomic DNA was
performed using Taq polymerase (New England Biolabs). Genomic_ENREF_25 DNA
from cultured mammalian cells was isolated using GeneJET Genomic DNA Purification
Kit (Thermo). General genetic engineering experiments were performed as described in
Sambrook and Russell (Sambrook and Russell 2001).
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CHAPTER 4
RESULTS

4.1

Genomic target-like sequences.

For our experiments we chose three FRT-like sequences that are located upstream
of the human δ-globin gene and within the δ-globin and β-globin genes: FL-61, FL-63, and
FL-71, respectively, which are separated from each other by 2.7 kb and ~7.5 kb,
respectively (Figure 2-5A and B).
These FRT-like sequences, as well as other genomic FRT-like sequences, can have
several potential upstream and downstream TAL recognition sequences since the
requirements for the TAL recognition sequences are quite relaxed – the only major
prerequisite is a thymine at the position N-1 of the sequence: 5’T (Lamb BM 2013). We
reasoned that to be useful in targeting Flp-TAL recombinases to the desired FRT-like
sequences and to be easily manageable from the technical point of view, the TAL module
has to recognize the DNA sequence of 15-24 bp in length. We also reasoned that the TAL
binding sequence should be separated from the recombinase binding element of the FRTlike sequence by 3 to 12 base pairs to avoid steric clashes between the hybrid recombinase
modules or their significant spatial separation.
Additionally, we reasoned that the length of the TAL binding sequences should
correlate with the degree of similarity between the Flp binding elements of the FRT-like
sequence and that of FRT: the weaker the similarity, the longer the TAL recognition
sequence.
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Based on the above considerations, we decided to test the TAL biding sequences of 15
bp in length (except for the upstream 24-bp TAL binding site for FL-71) that are separated
from FL-61, FL-63, FL-71 by 4-5 bp (Figure 4- 2C).
4.2

Evolution of Flp variants with strict and relaxed target specificity.

Over the course of our research we evolved a number of Flp variants that recognize
different genomic targets (e. a. Bolusani S 2006, Shultz JL 2011, L. F. Shah R 2015). In
addition to unique mutations, these variants contain a group of mutations that are usually
present in all variants. Most likely, these common mutations collectively relax the strict
target specificity of Flp and allow it to recombine not only FRT but also FRT-like
sequences. The unique mutations in these Flp variants either further relax or, in contrast,
narrow the variant’s target specificity.
The Flp variants that bear the common as well the unique mutations can be used to
speed up the evolution of the Flp variants with target-specific or target-relaxed phenotypes
if their genes are used as templates for generating shuffled variant libraries which can be
screened to identify the desired target specificity. The pool of the template variant genes
can be enhanced by including the library of the Flp genes that were randomized at codons
55, 58 and 59 since the amino acids at these positions contact the first four base pairs of
the Flp binding elements of FRT that were shown to be the most critical for the Flp-FRT
recognition (Shultz JL 2011).
Flp variants that are suitable for generating hybrid Flp-TAL recombinases, that is, those
with relatively low activity and with strict or somewhat relaxed target specificity, can be
evolved by one or two rounds of protein evolution using a pair of different but related
recombination sequences: a genomic FRT-like sequence and FRT. We tested this evolution
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approach using three recombining pairs: FL-61/FRT, FL-63/FRT, and FL-71/FRT, and
then compared the activity of the evolved Flp variants on the FL-61, FL-63, and FL-71
sequences.
To identify Flp variants with the desired properties we designed a screening system
that is composed of the inversion and deletion reporters that are used sequentially (Figure
4-1 A and B). The reporter cassettes in these vectors are flanked by the pair of the
recombination sites that are arranged in the head-to-head and head-to-tail orientations,
respectively. The inversion and deletion reporters have different purposes. The inversion
reporter is used to identify a large pool of Flp variants that are able to recombine both the
FRT-like sequence and FRT; these variants are selected by amplifying the Flp variant genes
in the inversion-positive configuration of the reporter (Figure 4-1 A). The deletion reporter
is used to screen the inversion-positive library of the Flp variants that are sufficiently active
to delete the reporter cassette in at least some vector molecules (Figure 4- 1 B).
The screen of the library of the shuffled Flp variants that bear the desired set of
mutations discussed above using the respective inversion and deletion reporters identified
several Flp variants that were able to recombine the FL-61/FRT, FL-63/FRT, and FL71/FRT pairs with reasonable efficiency. The variants that demonstrated the highest
activity on their respective recombination pairs were named FV61, FV63, and FV71 and
tested for their ability to recombine all three FRT-like sequences to identify the variants
with either strict or broad target specificity (Figure 4- 1D and E).
FV61, FV63, and FV71 responded differently when they were challenged with the
‘non-cognate’ FRT-like sequences (Figure 4- 1D and E). FV63 was the most specific and
was able to efficiently recombine only the FL-63 sequence; some minor recombination
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activity was seen on the FL-61 but the recombination activity on FL-71 was barely
detectable. FV71 was the least specific and was able to recombine all three FRT-like
sequences. FV61 was also able to recombine FL-61, FL-63, and FL-71, but we noticed
abnormalities in its phenotype: the pale blue colonies in the experiments with all FRT-like
sequences (Figure 4-1D) and the faint reporter bands in the FL-71 experiments (both
unrecombined and recombined, Figure 4-1E); they apparently indicate that FV61 binds to
DNA (or just to the FRT-like sequences) tighter than do FV63 and FV71. Off note, our
evolution experiments sometimes generate Flp variants with the FV61-like phenotype.
The mutational profile of FV61, FV63, and FV71 is shown in Figure 4- 3C. As
anticipated, these Flp variants bear a group of common mutations: at positions 35, 45, 50,
114, 295, 363. In addition, each variant has a set of unique mutations, some of which were
seen before in other target-specific Flp variants (positions 44, 62, 130, 173, 176, 193, and
324) while the other unique mutations are new (positions 3, 18, 75, 85, 157, 171, 213, and
290). In addition, FV61 and FV63 had the same set of mutations at positions 55, 58, and
59 which were different from that of FV71; the functional significance of this difference
requires further analysis. We also noted that the profile of mutations in FV61, FV63, and
FV71 is different from that of the Flp variants that were previously evolved to recombine
FL-61, FL-63, and FL-71 (Shultz JL 2011).
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Figure 4-1: Evolution of Flp-TAL recombinases. (A) Inversion assay. The reporter bears
an inversion cassette flanked by the recombination targets in the head-to-head orientation:
FL-61, FL-63, or FL-71 (marked as RT) and FRT* with the spacer either from FL-61, FL63, or FL-71, respectively. Upon expression of a recombination competent Flp variant, the
cassette is inverted so the gene that encodes this variant can be amplified. (B) Deletion
assay. The deletion reporter bears the lacZα cassette flanked by the recombination targets
in the head-to-tail orientation. If a Flp variant is able to delete the cassette, the resulting
bacterial cells will form white colonies when plated on the X-gal containing plates. (C)
Mutations in FV61, FV63, and FV71. (D) Activity of FV61, FV63, and FV71 on the FL61, FL-63, and FL-71 substrates. The assays were performed using the deletion reporter.
(E) Electrophoregram of the uniquely digested vector DNA isolated from the pooled
colonies in the respective plates shown in D. Ctr, control vectors; EV, expression vector;
RV, reporter vector; EV + RV, Flpe expression vector and the deletion reporter that bears
the FRT flanked lacZα cassette, which was completely deleted; M, DNA ladder.

4.3

Target-Specific Flp Variant Recombines FL-IL10A Sequence Pre-integrated
To test whether target-specific Flp variants can recombine their cognate DNA

sequences in mammalian genome, we chose well-characterized Flp variant FV7 (M. C.
Bolusani S 2006) that recognizes FL-IL10A (Figure 2-5 B) located upstream of the
human interleukin-10 gene. For these experiments, we generated a CHO cell line with
FL-IL10A singly integrated into genome.
A schematic of the assay to test the integration activity of FV7 is shown in Figure
4-1 A. The FL-IL10A site in the pre-integrated platform reporter pCMV-IL10A-DsRed is
located between the CMV promoter and the DsRed gene. The incoming reporter pIL10AEGFP bears the hybrid FRT/FL-IL10A site (Figure 4-2C) followed by the promoterless
EGFP gene. Upon integration of the incoming reporter into the FL-IL10A site, the EGFP
gene is transferred under the control of the CMV promoter, thus preventing the DsRed
gene from being expressed. This integration event can be detected by the appearance of
green, non-red cells.
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The integration activity of FV7 was tested by transfecting the reporter cells with
the incoming reporter and the FV7 expression vector. The experiments were performed in
6-well plates. 48 hours after transfection, the cells were expanded and screened for the
groups of green cells (Figure 4-2B). Only these groups and not individual green cells
were counted as productive integration events. Based on the number of groups of green
cells and the efficiency of the control transfection of an EGFP-expressing reporter similar
in size to pIL10A-EGFP, we estimated the efficiency of the FV7-mediated integration
into FL-IL10A as a fraction of the transfected cells. On average, in the one-sixth of the
expanded transfected cells we observed 17 integration-positive green, non-red colonies
(Figure 4-2 C). This number corresponded to about 0.1% of the transfected cells (Figure
4-2 C). In the expanded cells, in addition to the green, non-red cells, we also noticed rare
green/red colonies: on average, 1 colony per plate of the expanded cells; these colonies
were not analyzed. In the control experiments performed with the incoming reporter
alone, no green or green/red colonies were observed.
We expanded and analyzed 10 green, non-red colonies obtained as described
above. The integration events in all these colonies were confirmed by PCR (Figure 4-2
D) and sequencing of the integration-specific PCR products (Figure 4-2 E).
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Figure 4-2: FV7-mediated integration of a reporter into FL-IL10A pre-integrated into the
CHO genome. (A) Schematic outline of the integration assay. The horizontal blue and red
bars in panels (A) and (D) schematically represent the PCR products at the left junction
[LJ] and the right junction [RJ] of the integration product and the control PCR product of
the platform reporter [C2]. (B) Green colonies are formed after the transfected cells are
split and expanded. (C) The efficiency of the FV7-dependent integration is represented
by the green bar that shows the mean value of three experiments; the error bar indicates
standard deviation. (D) PCR analyses of a typical expanded green colony. LJ and C1
lanes show the results of the PCR analysis of the green cells and the original platform
cell, respectively, using the same primers that anneal on the CMV promoter and the
EGFP gene. RJ and C2, the PCR analysis of the green cells and the control platform cells
using the primers that anneal on the vector backbone and the DsRed gene. M, DNA
marker. (E) Representative sequencing snapshots of the recombination site regions in the
diagnostic PCR products LJ and RJ (panel D). The schematics of the recombination sites
and the surrounding sequences are shown above the sequencing snapshots.
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4.4

Flp-TAL recombinase architecture.

The mode of binding of the Flp recombinase to its native recognition sequence, Flp
Recombination Target, or FRT, specifies the mode of binding of the hybrid Flp-TAL
recombinase to its target (Figure 2-12A): the Flp module binds to the inner segments of the
target sequence, which constitute the actual FRT-like sequence, while the TAL module
binds the outer segments of the target sequence.
The analysis of the Flp/DNA and the TAL DBD/DNA complexes (Chen, et al 2000,
Mak AN 2012) shows that, in principle, the TAL module can be fused to either the Cterminus or to the N-terminus of the module Flp, thus creating two hybrid recombinase
architectures: Flp-TAL and TAL-Flp (Figure 2-12B). In principle, both Flp-TAL and TALFlp are capable of binding to the head-to-tail and the tail-to-tail arrangements of the target
sequences provided the length of the linker that connects the modules is sufficiently long
(Figure 2-12B). However, in the compact modes of the Flp-TAL and TAL-Flp architectures
(that is, when the linker that connects the modules is short) Flp-TAL is able to bind to the
‘convenient’ head-to-tail arrangement of the target sequence while TAL-Flp can bind to
the ‘inconvenient' tail-to-tail arrangements of the target sequences (Figure 2-12B). The
‘convenience’ here is the property of the target sequence arrangement that describes (e. a.
Miller JC 2011) how easy it is to increase the length of the DNA sequence to which the
TAL module binds and (e. a. Cong L 2013) how easy it is to avoid steric clashes between
the hybrid recombinase modules without changing the length of the inter-modular linker
when the TAL modules with different lengths of the C-terminal domain are used.
Considering all the features of the hybrid recombinases architectures, we decided to
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proceed with the Flp-TAL architecture and the head-to-tail organization of the target
sequence (Figure 2-12B).
In the Flp-TAL design we utilized the TAL DNA-binding domain and the intermodular linker that were proven in other hybrid enzymes (Figure 2-12C). The full-size Flp
recombinase variant was fused to the TAL core DNA-binding domain that starts at the
position +152 (Δ152 truncation of the N-terminal segment of the TAL effector) and ends
at the position +95 of the C-terminal segment of TAL effector (e. a. Miller JC 2011). The
Flp and TAL modules were connected via linker L6 that was shown to support the highest
level of activity of the zinc-finger recombinases (Akopian A 2003).
4.5

Flp-TAL variants can integrate a reporter into the desired locations in the
human genome.
To test whether Flp-TAL recombinases are capable of targeting FRT-like sequences

in their native environment, we fused the FV61, FV63, and FV71 variants with their
respective TAL modules (Figures 2-12A and 2-5C). Since the TAL modules in the FlpTAL recombinase have to be specific for both upstream and downstream TAL recognition
sequences of the FRT-like sequence, two Flp-TAL variants for each fusion recombinase
were engineered: Flp-TAL(L) and Flp-TAL(R), Figure 2-12A. For the sake of simplicity,
the left and the right Flp-TAL variants of FV61, FV63, and FV71 will be collectively called
FV61-TAL, FV63-TAL, and FV71-TAL, respectively.
The targeting activity of the hybrid Flp-TAL recombinases was analyzed via
integration and deletion assays (Figures. 4-3 and 4-4). The schematic of the integration
assay is shown in Figure 4- 3A. The reporter vector pTarget bears three transcriptional units
that express EGFP, hygromycin B phosphotransferase gene (hygro R), and DsRed. In this
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reporter, the hybrid FRT/FL-61 (or FRT/FL-63) site is located between the CMV promoter
and the EGFP gene while the hybrid FRT/FL-71 site is positioned between the EF1α
promoter and the DsRed gene.
If FV61-TAL (or FV63-TAL) integrates pTarget into the native FL-61 (or FL-63)
sequence, the EGFP gene loses its promoter and thus cannot be expressed. The resultant
cells should be therefore red and not green (Figure 4- 3A). Alternatively, if FV71-TAL is
capable of integrating pTarget into the native FL-71, the DsRed gene loses its promoter
and cannot be expressed. The resultant cells should be just green (Figure 4-3A).
To test the integration activity of the Flp-TAL recombinases, we co-transfected
HEK293 cells with the pTarget reporter and the vector that express either FV61-TAL,
FV63-TAL, or FV71-TAL. 48 hours post-transfection, 1/10 of the cells were transferred
into medium supplemented with hygromycin and incubated for about 10 days until the
hygroR colonies are formed. Four types of colonies were observed: with no color, green
and red, just green, and just red. We did not note apparent differences in the ratios of these
colony types in the experiments with FV61-TAL, FV63-TAL, and FV71-TAL.
To determine if the Flp-TAL recombinases are capable of integrating the reporter into
the desired FRT-like sequences, the hygromycin resistant colonies were pooled and their
genomic DNA isolated and subjected to the PCR analysis, which confirmed the correct
integration events (Figure 4-3B).
Importantly, the control experiments with the ‘plain’ Flp variants FV61, FV63, and
FV71 did not yield detectable integration of the reporter into the respective FRT-like
sequences.

47
To determine the efficiency of integration, we performed a series of integration
experiments as described above but instead of pooling all hygromycin resistance colonies
we expanded only either just red colonies (FV61-TAL and FV63-TAL experiments) or just
green colonies (FV71-TAL experiments) and subjected them to the PCR analysis. These
experiments revealed that the hybrid recombinases integrated the reporter vector, on
average, in about 0.1% of the transfected cells.
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Figure 4-3: Flp-TAL variants can target FL61, FL63, and FL71 in unmodified HEK-293
cells. (A) Schematics of the integration assays. The reporter can be integrated either into
FL-61, FL-63, or FL-71 depending on the specificity of the Flp-TAL variant. Upon
integration of pTarget into FL-61 or FL-63 the resultant cells become hygromycin resistant
and red, while if integrated into FL-71, the cells become hygromycin resistant and green
(images of the individual expanded hygroR/red and hygroR/green colonies are shown as
examples). LJ and RJ show the locations of the diagnostic PCR products at the left and
right junctions of the integrated reporter and genomic DNA. (B) PCR analysis of the pooled
hygroR colonies. LJ, RJ, the PCR analysis of the left and right junctions of pTarget
integrated into the respective genomic sequences; M, DNA ladder. (C), (D), and (E)
Sequencing of the integration-specific PCR products LJ and RJ of pTarget integrated into
FL-61, FL-63, and FL-71, respectively, confirmed their identity.

4.6

FV71 can be fused to the TAL modules with different target specificity to
recombine different FRT-like sequences in the human genome.
We next tested whether FV71, which was able to recombine different FRT-like

sequences in bacteria (Figure 4-3E and D), could also recombine these sequences in their
native genome environment. For this, we fused FV71 with the respective TAL modules
that are specific for either FL-61 or FL-63 (Figure 2-5C) to obtain the FV71-TAL61 and
FV71-TAL63 variants, respectively. We then performed the integration experiments as
described in the previous section and found that FV71-TAL61 and FV71-TAL63 were able
to target FL-61 and FL-63 as efficiently as did FV61-TAL and FV63-TAL (Figure 4-4).
In parallel, we tested if FV61, which showed an apparent tight binding phenotype in
bacterial cells (Figure 4-3E and D), was able to target FL-71 if fused to the respective TAL
module. Despite extensive experimenting we were unable to detect FV61-TAL71mediated integration of the reporter vector into FL-71.
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4.7

Flp-TAL recombinases can delete genome fragments.

Finally, we tested the ability of the Flp-TAL recombinases to delete large genome
fragments. For this we utilized the property of the pTarget vector to bear two different FRTlike sequences (Figure 4-4 A). Upon integration of the vector into one of the respective
genomic FRT-like sequences, the other vector-borne FRT-like sequence can be used to
delete a DNA fragment that is located between this sequence and the corresponding
genomic FRT-like sequence (Figure 4-4A).
In the deletion assays we used the expanded integration-positive red cells that were
obtained in the FV61-TAL integration experiments (Figure 4-4). These cells were
transfected with the vector that expresses the FV71-TAL recombinase, then expanded and
subjected to the PCR analysis to assess the ratio of the cells, in which the 14.7 kb DNA
fragment was deleted. The analysis of the sequentially diluted genomic DNA revealed that
the deletion occurred, on average, in about 10% of the transfected cells (Chaikind B 2016).
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Figure 4-4: Flp-TAL variants can delete a genome fragment. (A) Schematic of the deletion
assay. Upon expression of FV71-TAL, the DNA fragment that is located between two FL71 sequences and that contains part of the reporter and genomic DNA gets deleted. (B)
PCR analysis of the FV71-TAL treated cells which bear pTarget integrated into FL-61. LJ
and RJ are the left and right junctions of the reporter and the genomic DNA. CLJ and CRJ
control PCR analyses of the original cells using the same primers as in lanes LJ and RJ; M,
DNA ladder. (C) Sequencing of the deletion-specific PCR product RJ confirmed its
identity.

CHAPTER 5
DISCUSSION
The successful use of Flp variants as a means of gene therapy depends to a large
extent on the recombination activity in human cells. We have tried to express activity of
the evolved recombinase variants in a variety of different cells with FV7 to test if there
was any difference. A375(Human malignant melanoma), 293A(subclone of the 293 Cell
Line), CHO-TD1(Chinese hamster ovary cell), A549(Adenocarcinomic human alveolar
basal epithelial cells), and NIH 3t3(Embryonic mouse fibroblast) cell lines were tested.
Among them, 293A is the easiest to transfect, and the CHO cells show the highest
recombination activity. The recombination reaction can be easily performed in CHO cell
lines. In human cells, the activity is not as high as CHO cell lines. The recombination
activity in 293 cells is acceptable. We have great hope in 549 cells, because the cell line
can theoretically express hemoglobin, at least on the RNA level. But our tests show that,
Flp variants are very inactive in both 549 and 375 cell lines. Even the deletion reactions
are difficult to observe in 549 and 375 cell lines.
A prerequisite for recombination reaction is the completion of transfection. For
RMCD rearrangement, it is not an easy task to transfect at least three plasmids
(templates, two-stage expression plasmids) into the cells synchronously and to ensure
their activity. Therefore, the optimization of transfection is essential for this experiment.
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A paradox is that too high a transfection rate has a somewhat negative side for
recombination reactions.
Excessive free-form reporting plasmids can cause significant problems when
editing cellular genomic DNA. We must continually culture the cells for multiple
generations and, by sometimes being selected by antibiotics, remove those cells which
carry the episomal plasmid that contains the reporter gene. Even so, the interference of
the episomal reporting plasmid with the DNA detection results cannot be completely
eradicated. We have also tried to add a gene which induces cell suicide in the reporter
plasmid to ensure that suicide genes were activated on plasmids that were not integrated
in the genome. The experiment ended with the complete destruction of the cells. Besides,
the problem of fluorescent fading during the test also troubled us. We believe that the use
of different fluorescent genes or the use of specific equipment such as FAC will
significantly help the experiment.
Since shearing and integration are inherently reversible reactions, sometimes after
the reporter plasmids have been integrated into the genomic DNA, there is a risk of the
reporter gene being re-cut out by the same recombination reaction. To keep high
efficiency, the concentration of working recombinase should be high. To reduce the
reverse reaction of shearing, the concentration of recombinase should be as low as
possible. The best working concentration of recombinase transfection still needs to be
tested by experiments.
The activity of the Flp variants is not very satisfactory in human cells. We suspect
the reason is that the DNA of eukaryotes is always under high packaging. We used
CRISPR/CAS9 and some molecular factors which induce cells to become iPSC, so the
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DNA package opens. Insulin has been tried for the same purpose. We have discovered
that sometimes insulin can even cause recombination reactions in A375 cell lines, but this
result is not stable and is not repeatable. TALEN as nucleases are also used to cut DNA
in hopes of opening the package of genomic DNA, but the effect is not apparent.
It can be seen from the results that the fusion of TAL domain considerably
increases the activity of Flp variants. The addition of the NLS sequence can increase the
activity of Flp variant 4-10 fold. A suitable TAL structure will increase activity by nearly
10 times more. However, the "appropriate" TAL can only be obtained through testing.
The length of the TAL domain, and the distance between the TAL-binding site and the
recombinase domain can also effect Flp variants’ activity. Some Flp variants prefer an
RVD of 15 or 18 nucleotides. For some Flp variants, the ultra-long 24 RVD has the most
activity. Some Flp variants, even 12-length RVD, can achieve a good reinforcement.
For the same locus of Flp variants, the TAL domain blended on the left, but the
right sides were completely different and seemed to be unrelated. We hypothesize that the
fusion of TAL and Flp variants restrict Flp variants in site binding. But it is not easy to
find a particular law for this restriction.
The best performing Flp variants in bacteria often perform badly in eukaryotic
cells. Those Flp variants which play well in eukaryotic cells often have up to 80% of cell
discoloration in bacterial colony screening. For those Flp variants with a discoloration
rate of more than 90%, the activity is entirely lower than the variants of only 80% or
below 80% discoloration when tested in the eukaryote.
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